Tri-Heal (TB-500 + BPC-157 + KPV) (45mg)
Tri-Heal is a research peptide blend that combines TB-500 (25 mg), BPC-157 (10 mg), and KPV (10 mg) for advanced tissue repair and inflammation regulation. TB-500 is involved in cell migration and angiogenesis, BPC-157 in angiogenesis and gastroprotection, and KPV in potent anti-inflammatory action. Administered subcutaneously once daily with gradual titration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Tri-Heal combines three peptides with complementary mechanisms. **TB-500** (Thymosin β4) acts as a natural repair factor, inhibiting inflammation and apoptosis while promoting angiogenesis, cell migration, and extracellular matrix remodeling. **BPC-157** enhances healing via VEGFR2/Akt-eNOS pathway activation, increasing nitric oxide production and angiogenesis while stimulating fibroblast activity. **KPV** (Lys-Pro-Val), a tripeptide derived from α-MSH, provides anti-inflammatory action by reducing NF-κB activation and inflammatory cytokines. The combination simultaneously addresses healing, angiogenesis, and inflammation.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → 15 mg/mL (15,000 mcg/mL).
- Typical Daily Range: 500–2,000 mcg once daily (8-week gradual titration).
- Storage: Lyophilized: −20 °C · after reconstitution: 2–8 °C · avoid freeze-thaw cycles.
Typical 8-Week Protocol (3 mL = 15 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 500 mcg | 3.3 Units (0.03 mL) |
| Weeks 3–4 | 1,000 mcg | 6.7 Units (0.07 mL) |
| Weeks 5–6 | 1,500 mcg | 10 Units (0.10 mL) |
| Weeks 7–8 | 2,000 mcg | 13.3 Units (0.13 mL) |
Studies report administration once daily subcutaneously. For doses ≤10 units (≤0.10 mL), use 30- or 50-unit syringes for greater accuracy.
Reconstitution Steps
- Draw up 3.0 mL of bacteriostatic water with a sterile syringe.
- Slowly inject down the side of the vial · avoid foaming.
- Gently swirl until fully dissolved (do not shake vigorously).
- Note the date and concentration (15 mg/mL) · refrigerate at 2–8 °C, protected from light.
Protocol Overview
- Objective: Support tissue repair, regeneration, and inflammation regulation through synergistic peptide action.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16 weeks if needed).
- Storage: Lyophilized in freezer · reconstituted in refrigerator · avoid freeze-thaw cycles.
Dosing Protocol
- Start: 500 mcg daily · increase by 500 mcg every 2 weeks.
- Target: 1,500–2,000 mcg daily by weeks 5–8.
- Frequency: Once daily (subcutaneously).
- Cycle Duration: 8–12 weeks · optional extension to 16 weeks.
- Break between cycles: After the cycle, a 2–4 week break is recommended. The break prevents tolerance to the healing peptides in the blend.
Washout & Cycle Restart
When can I restart?
After the cycle, a 2–4 week break is recommended. The break prevents tolerance to the healing peptides in the blend.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: −20 °C or below in dry, dark conditions.
- Reconstituted: 2–8 °C · use within 4 weeks · avoid freeze-thaw cycles.
- Allow vials to reach room temperature before opening.
Important Notes
Potential Benefits & Side Effects
Potential Benefits:
- TB-500: Promotes cellular proliferation, angiogenesis, and tissue repair.
- BPC-157: Accelerates musculoskeletal healing, stimulates fibroblasts.
- KPV: Reduces inflammatory cytokines, effective in models of epithelial inflammation.
- Generally very well-tolerated based on preclinical studies.
Potential Side Effects:
- Potential mild injection site reaction (redness, transient discomfort).
- Human clinical data for this specific combination is limited.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis
Thymosin β4 regulates angiogenesis and cell migration. Theoretical concern that it may favor growth of existing tumors, though no clinical evidence exists.
📄 Ann NY Acad Sci 2007Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010Immunosuppression with chronic use
KPV (α-MSH fragment) is strongly anti-inflammatory. Theoretical risk of reduced immune surveillance with long-term use. No clinical studies in humans.
📄 FEBS Lett 2005References
- Annals of the NY Academy of Sciences (2012) — Thymosin β4 accelerates dermal healing
View Source - HSS Journal / PMC (2025) — BPC-157 in orthopedic sports medicine
View Source - Molecular Therapy Methods / PMC (2017) — KPV interaction in the treatment of ulcerative colitis
View Source - Frontiers in Endocrinology (2021) — Progress in the function and application of Thymosin β4
View Source - Journal of Orthopaedic Research (2003) — BPC-157 accelerates Achilles tendon healing
View Source
External Sources & Regulatory Status
Regulatory Approvals
Compounded blend — Not evaluated as a standalone medicine
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →